X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.
Lead Product(s): EOS-984
Therapeutic Area: Oncology Product Name: EOS-984
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions.
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Product Name: GSK4428859A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Product Name: EOS-448
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration June 14, 2021
Details:
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Product Name: EOS-448
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
Details:
The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Product Name: EOS-850
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 24, 2020
Details:
EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Product Name: EOS-448
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Company to present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at AACR conference.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint.
Lead Product(s): EOS-850
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 01, 2020
Details:
The Phase 1/2 Study is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers.
Lead Product(s): EOS-448
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
